Cited by Steroid treatment for COVID-19: Suitable dose and patients

Steroid treatment for COVID-19: Suitable dose and patients DOI

et al.

Lung India, Journal Year: 2023, Volume and Issue: 40(5), P. 481 - 482

Published: Aug. 28, 2023

Coronavirus disease 2019 (COVID-19) had the largest worldwide use of steroid treatment in history medicine. Although steroids COVID-19 started with start pandemic, it became rampant after Randomized Evaluation Therapy (RECOVERY) trial.[1] This trial reported that as compared to usual care, low-dose dexamethasone (6 mg daily for 10 days) reduced mortality by one-third patients receiving mechanical ventilation (29.3% vs 41.4%; rate ratio: 0.64 [95% CI, 0.51–0.81]) and one-fifth supplemental oxygen (23.3% 26.2%; 0.82 0.72–0.94]) but no benefit among not respiratory support (1.19 0.91–1.55]). The findings this were further confirmed a meta-analysis[2], thereafter, first-line almost all guidelines worldwide. However, many centres, particularly India other Asian countries, using higher doses including pulse dose hospitalised whether hypoxaemic or non-hypoxaemic could be an underlying cause increased disease.[3] More recently, RECOVERY-II days), high-dose (20 5 days followed was associated (19% 12%; 1.59 CI 1.20–2.10]) non-COVID-19 pneumonia (10% 6%, absolute risk: 3.7% CI: 0·7–6·6]) clinical hypoxia simple oxygen.[4] non-COVID high clarified trial. As per our recent meta-analysis, impair host immunity make them vulnerable secondary infections, COVID-19-associated pulmonary aspergillosis (CAPA), which may these patients.[5] has association hyperglycaemia (22% 14%; difference: 7.4% 3.2–11.5]), is also well-recognised risk factor CAPA.[6] development CAPA infections represents complications responsible treated steroids.[6,7] Other publications have prolonged (i.e., >10 CAPA.[8] Furthermore, injudicious mucormycosis (CAM). A large multicentre case–control study on CAM across 25 hospitals concluded cumulative glucocorticoid (odds ratio [OR]: 1.006, 95% 1.004-1.007), diabetes mellitus [OR: 6.72, 5.45–8.28] diabetic ketoacidosis during 4.41, 2.03–9.60]) important controllable factors outbreak.[9,10] So, should highly discouraged prevent mucormycosis. Similarly, avoided can augment inducing CAPA, CAM, and/or adverse effects. Sometimes, are unnecessarily used chase unusual inflammatory markers non-genuine indications without actual presence persistent hypoxia. Hypoxia too must properly documented, just one two low readings oximeter, sometimes erroneous. In conclusion, achieve minimise hazardous effects, suitable judicious limited period only, only those having well defined hypoxemia. Financial sponsorship Nil. Conflicts interest There conflicts interest.

Language: Английский

Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients DOI

Simon Feys, Agostinho Carvalho, Cornelius J. Clancy

et al.

The Lancet Respiratory Medicine, Journal Year: 2024, Volume and Issue: 12(9), P. 728 - 742

Published: July 15, 2024

Language: Английский

Citations

Covid-19-associated pulmonary aspergillosis in mechanically ventilated patients DOI

Guangting Zeng, Linlin Wang

Annals of Intensive Care, Journal Year: 2024, Volume and Issue: 14(1)

Published: March 1, 2024

Language: Английский

Citations

Posaconazole for Prevention of COVID‐19‐Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients: A European Multicentre Case–Control Study (POSACOVID) DOI

Juergen Prattes, Daniele Roberto Giacobbe, Cristina Marelli

et al.

Mycoses, Journal Year: 2025, Volume and Issue: 68(1)

Published: Jan. 1, 2025

This study investigated the impact of posaconazole (POSA) prophylaxis in COVID-19 patients with acute respiratory failure receiving systemic corticosteroids on risk for development COVID-19-associated pulmonary aspergillosis (CAPA). The primary aim this prospective, multicentre, case-control was to assess whether application POSA mechanically ventilated reduces CAPA development. All consecutive from centre 1 (cases) who received as standard-of-care were matched one subject 2 and 3 did not receive any antifungal prophylaxis, using propensity score matching following variables: (i) age, (ii) sex, (iii) treatment tocilizumab (iv) time at risk. Eighty-three identified 166 controls. In cohort, incidence rates 1.69 (centre 1), 0.84 2) 7.18 3) events per 1000 ICU days. multivariable logistic regression analysis, presence an EORTC/MSGERC factor admission (OR 4.35) versus 6.07; 95% CI 1.76-20.91; p = 0.004) associated increased CAPA. No registered 1. depends baseline rate, which varies widely between centres. Future trials should therefore investigate targeted (e.g., stratified high-prevalence centres or high-risk patients) patients. NCT05065658.

Language: Английский

Citations

A bibliometric and visual analysis of the research status and hotspots of Pulmonary Aspergillosis based on Web of Science DOI

Jun Li, Qingjun Zhu, Huixin Yan

et al.

Diagnostic Microbiology and Infectious Disease, Journal Year: 2025, Volume and Issue: 112(4), P. 116864 - 116864

Published: April 20, 2025

Language: Английский

Citations

Machine Learning Methods Based on Chest CT for Predicting the Risk of COVID-19-Associated Pulmonary Aspergillosis DOI

Jiahao Liu, Juntao Zhang, Huaizhen Wang

et al.

Academic Radiology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

Clinical characteristics and prognosis of COVID-19- associated invasive pulmonary aspergillosis in critically patients: a single-center study DOI

Shuang Xiao, Ning Gan, Han Xiao

et al.

Frontiers in Cellular and Infection Microbiology, Journal Year: 2025, Volume and Issue: 15

Published: April 22, 2025

A single-center retrospective study was conducted according to the latest diagnostic criteria of European Consortium for Mycology in Medicine/International Society Human and Animal Mycoses (ECMM/ISHAM) Consensus, which describes clinical characteristics, factors influencing prognosis a group patients with COVID-19 (Omicron variant) combined invasive pulmonary mycoses onset disease at end 2022. This retrospectively analyzed data related 58 hospitalized severe pneumonia due infection admitted ICU critical care medicine, respiratory ICU, Department Infections First Affiliated Hospital Soochow University from December 1, 2022, January 31, 2023. CAPA defined ECMM/ISHAM consensus criteria. Our compared microbiological characteristics associated risk fungal infections performed univariate multivariate analyses mortality COVID-19-Associated Pulmonary Aspergillosis (CAPA). 17 (29.3%) critically ill were diagnosed CAPA, 10 (58.82%) Probable 7 (41.18%) Possible CAPA. Among this Aspergillus strains, fumigatus strains found 13 cases (76.47%) niger 4 (23.53%). had concomitant bacterial rate 57.14% (4/7), Acinetobacter baumannii most common pathogen. galactomannan assay bronchoalveolar lavage fluid (BALF) 5 100% (5/5) positivity rate, two or more serum (GM) assays patients, probability favorable results both 41.2% (7/17). The 60-day 52.9% (9/17), whereas non-CAPA 24.4% (10/41), statistically different (P = 0.035). Diabetes mellitus 0.018, OR: 5.040 (95% CI: 1.314-19.337)), renal insufficiency (P=0.002, 11.259 2.480-51.111)), chronic obstructive (COPD) 0.003, 6.939 1.963-24.531)), elevated interleukin-6 (IL-6) 0.022, 4.160 1.226~14.113)), mechanical ventilation 0.002, 8.100 (95%CI: 2.132~30.777)), increased duration steroids use 1.071 1.010~1.135)), cumulative dose ((P < 0.001, 1.012 1.009~1.015)), tocilizumab 0.020, 11.480 2.480~51.111)), length hospitalization 0.021, 1.038 1.006 1.071)), increase type antibiotics used 1.603 1.181 2.176)) occurrence infections, not, baricitinib hypertension did not have significant effect on > 0.05). Patients higher their prolonged patients. all-cause 52.9%. We also potential mortality, including 0.040 10.500, 1.115 98.914)), advanced age 0.043 1.212, 1.460)), significantly CRP level 0.042 1.043, 1.002~1.078)) worse prognosis. Steroids use, gender, diabetes patient death

Language: Английский

Citations

Multiple Administration of Dexamethasone Possesses a Deferred Long-Term Effect to Glycosylated Components of Mouse Brain DOI

Stanislav D. Aladev, Dmitry K. Sokolov, Anastasia V. Strokotova

et al.

Neurology International, Journal Year: 2024, Volume and Issue: 16(4), P. 790 - 803

Published: July 22, 2024

Glucocorticoids are used during glioblastoma treatment to prevent the cerebral edema effect surrounding normal brain tissue. The aim of our study was investigate long-term effects multiple administrations glucocorticoids onto glycosylated components (proteoglycans and glycosaminoglycans) extracellular matrix glucocorticoid receptor (GR,

Language: Английский

Citations

High-dose corticosteroid therapy in COVID-19: the RECOVERY trial DOI

Zia Hashim, Alok Nath, Naresh Kumar Tripathy

et al.

The Lancet, Journal Year: 2024, Volume and Issue: 403(10434), P. 1337 - 1338

Published: April 1, 2024

Language: Английский

Citations

Comparative Analysis of the Clarus Aspergillus Galactomannan Enzyme Immunoassay Prototype for the Diagnosis of Invasive Pulmonary Aspergillosis in Bronchoalveolar Lavage Fluid DOI

Sarah Sedik, Johannes Boyer, Matthias Egger

et al.

Mycopathologia, Journal Year: 2024, Volume and Issue: 189(4)

Published: July 18, 2024

Galactomannan (GM) testing using Platelia Aspergillus enzyme immunoassay (Platelia AGM) from bronchoalveolar lavage fluid (BALF) aids in early diagnosis of invasive pulmonary aspergillosis (IPA). Globally, only a minority laboratories have the capability to perform on-site GM testing, necessitating accessible and affordable alternatives. Hence, we conducted comparative evaluation new clarus prototype (clarus AGM prototype) with BALF samples.

Language: Английский

Citations

Risk of COVID-19-associated pulmonary aspergillosis: time for a nuanced approach to antifungal prophylaxis? DOI

Martin Hoenigl, Juergen Prattes

The Lancet Respiratory Medicine, Journal Year: 2024, Volume and Issue: 12(3), P. 183 - 185

Published: Jan. 4, 2024

Language: Английский

Citations